{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05635643",
            "orgStudyIdInfo": {
                "id": "SRF114-101"
            },
            "organization": {
                "fullName": "Coherus Biosciences, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of CHS-114 in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-chs-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-14",
            "studyFirstSubmitQcDate": "2022-11-22",
            "studyFirstPostDateStruct": {
                "date": "2022-12-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Coherus Biosciences, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.",
            "detailedDescription": "This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in participants with advanced solid tumors, that will be conducted in 3 parts:\n\n* Arm 1a: CHS-114 monotherapy dose-escalation portion of the study will enroll approximately 25 participants with advanced solid tumors.\n* Arm 1b: CHS-114 monotherapy expansion cohort(s) will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of CHS-114 in indication specific cohort(s). Up to approximately 10 participants will be enrolled.\n* Arm 2: CHS-114 + toripalimab combination dose-escalation portion of the study will evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of CHS-114 in combination with toripalimab in indication specific cohort(s). Up to approximately 6-12 participants will be enrolled."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Head and Neck Squamous Cell Carcinoma"
            ],
            "keywords": [
                "metastatic solid tumors",
                "advanced solid tumors",
                "Phase 1",
                "SRF114",
                "CCR8",
                "safety",
                "efficacy",
                "immunotherapy",
                "cancer",
                "immuno-oncology",
                "CHS-114"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 47,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1a: CHS-114 Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Arm 1 monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CHS-114 as monotherapy in up to 25 participants with advanced solid tumors, to determine the recommended dose for expansion (RDE).",
                    "interventionNames": [
                        "Drug: CHS-114"
                    ]
                },
                {
                    "label": "Arm 1b: CHS-114 Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Arm 1b monotherapy expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 monotherapy at 2 dose levels (potential recommended dose for expansion \\[RDE\\]) in up to 5 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).",
                    "interventionNames": [
                        "Drug: CHS-114"
                    ]
                },
                {
                    "label": "Arm 2: CHS-114 + toripalimab Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Arm 2 combination dose expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 in combination with toripalimab at 2 dose recommended Phase 2 dose \\[RDE\\] levels in up to 6 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).",
                    "interventionNames": [
                        "Drug: CHS-114",
                        "Drug: toripaliamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CHS-114",
                    "description": "CHS-114",
                    "armGroupLabels": [
                        "Arm 1a: CHS-114 Dose Escalation",
                        "Arm 1b: CHS-114 Dose Expansion",
                        "Arm 2: CHS-114 + toripalimab Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "toripaliamab",
                    "description": "toripalimab-tpzi",
                    "armGroupLabels": [
                        "Arm 2: CHS-114 + toripalimab Dose Expansion"
                    ],
                    "otherNames": [
                        "Loqtorzi"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT)",
                    "description": "Evaluation of rate of DLT of CHS-114 as a monotherapy, or in combination with toripalimab",
                    "timeFrame": "Assessed during first 21 days of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "[Arms 1a and 1b] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs).",
                    "description": "Safety and tolerability of CHS-114 as monotherapy, and in combination with toripalimab, will be assessed by summarizing adverse events (AEs) and will be based on treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Anti-drug Antibodies (ADAs) to CHS-114",
                    "description": "Serum will be collected and assessed for the development of ADAs to CHS-114",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a, 1b, and 2] Pharmacokinetics (PK) of CHS-114",
                    "description": "Serum concentrations of CHS-114 will be collected and analyzed to evaluate the PK of CHS-114 and in Arm 2 toripalimab.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a, 1b, and 2] Confirmed objective response rate (ORR)",
                    "description": "Confirmed objective response rate (ORR) based on RECIST v1.1",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a, 1b, and 2] Duration of response (DoR)",
                    "description": "Duration of response (DoR) based on RECIST v1.1. DoR is defined as the time from the first documented response (CR or PR) to documented disease progression as determined by RECIST v1.1 or death.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a, 1b, and 2] Disease control rate (DCR)",
                    "description": "Disease control rate (DCR) based on RECIST v1.1. DCR is defined as the percentage of patients with CR, partial PR, or stable disease lasting a minimum of 12 weeks.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a, 1b, and 2] Progression-free survival (PFS)",
                    "description": "Progression-free survival (PFS) based on RECIST v1.1. PFS is defined as the time from the first treatment on study with study drug to documented disease progression as determined by RECIST v1.1 or death.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "[Arms 1a and 1b] Changes in FOXP3 levels in participants undergoing pretreatment and on-treatment tumor biopsies",
                    "description": "Cellular FOX3P expression within the tumor will be collected and analyzed in participants who are undergoing pretreatment and on-treatment biopsies",
                    "timeFrame": "Up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria - Arms 1a, 1b, and 2\n\n* Participants must be \u2265 18 years of age.\n* For Arm 1a only, locally advanced or metastatic (Stage IV) solid tumor that has progressed during or after standard therapy and for whom no available therapies are appropriate (based on the judgment of the Investigator).\n* At least 1 measurable lesion per RECIST 1.1.\n* Lesions previously treated with radiation or other forms of locoregional therapy must show radiographic evidence of disease progression to be used as a target lesion.\n* Washout period from the last dose of previous anticancer therapy (chemotherapy, biologic, or other investigational agent) to the initiation of study drug must be \\> 5 times the half-life of the agent or \\> 21 days (whichever is shorter).\n* Resolution of non-immune-related AEs secondary to prior anticancer therapy (excluding alopecia and peripheral neuropathy) to \u2264 Grade 1 per NCI-CTCAE version 5.0 or higher, and complete resolution of immune-related AEs secondary to prior checkpoint inhibitor therapy.\n* Serum creatinine clearance \u2265 30 mL/min per Cockcroft-Gault formula.\n* Total bilirubin \u2264 1.5 \u00d7 ULN (\u2264 3 \u00d7 ULN if elevated because of Gilbert's syndrome and \u2264 2 \u00d7 ULN for patients with hepatocellular carcinoma \\[HCC\\] or patients with known liver metastases).\n* Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) \\< 2.5 \u00d7 ULN or \\< 5 \u00d7 ULN for patients with known liver metastases.\n* Adequate hematologic function, defined as absolute neutrophil count \u2265 1.0 \u00d7 109/L, hemoglobin \u2265 9.0 g/dL, and platelet count \u2265 75 \u00d7 109/L.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Ejection fraction \u2265 50%, as measured by echocardiogram, multigated acquisition scan, nuclear stress test, or equivalent modality.\n* Willingness of male and female patients who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control for the duration of the study treatment period, including 90 days after the last dose of CHS-114, 4 months after the last dose of toripalimab; male patients must refrain from donating sperm during this period. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception. Azoospermic male patients and WCBP who are continuously not heterosexually active are exempt from contraceptive requirements.\n\nAdditional Inclusion Criteria - Arms 1b and 2 only\n\n* Histologically or cytologically confirmed advanced or metastatic HNSCC that has progressed during or after a platinum-based chemotherapy and/or a programmed cell death receptor (PD)-1 or PD ligand 1 (PD-L1) targeting agent (separately or in combination therapy).\n* Metastatic or locoregionally recurrent HNSCC malignancy that is incurable by surgery or radiotherapy.\n* Arm 1b only, participants must have tumor tissue that is accessible for pretreatment and on-treatment tumor biopsy in the opinion of the Investigator and be willing and consent to undergo pretreatment and on-treatment biopsies per protocol.\n\nKey Exclusion Criteria - Arms 1a, 1b, and 2\n\n* Previously received an anti-CCR8 antibody or anti-CCR8 targeted therapy.\n* History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody therapy or any excipient in the study drugs.\n* Major surgery within 4 weeks prior to Screening.\n* Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes, symptomatic fistula) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study.\n\nAdditional Exclusion Criteria - Arms 1b and 2 only\n\n* Received \\> 4 prior systemic regimens for advanced/metastatic disease.\n* Nasopharyngeal carcinoma or nasal cavity malignancies other than HNSCC (eg, adenocarcinoma and variants, neuroendocrine tumors, mucosal melanoma).\n* Receiving chronic anti-coagulation therapy (eg, warfarin, enoxaparin) that cannot be safely discontinued temporarily for the required biopsies (only for patients who provide tumor biopsies).",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Hillary O'Kelly",
                    "role": "CONTACT",
                    "phone": "805-551-1699",
                    "email": "hokelly@coherus.com"
                },
                {
                    "name": "Koho Izuka, MD",
                    "role": "CONTACT",
                    "phone": "732-266-3521",
                    "email": "kizuka@coherus.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Koho Izuka, MD",
                    "affiliation": "Coherus BioSciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford Cancer Center",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Winters",
                            "role": "CONTACT",
                            "phone": "650-723-6372",
                            "email": "ewinters@stanford.edu"
                        },
                        {
                            "name": "A. Dimitrios Colevas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "University of Louisville",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Stacy",
                            "role": "CONTACT",
                            "phone": "502-217-5244",
                            "email": "jennifer.stacy.1@louisville.edu"
                        },
                        {
                            "name": "Rebecca Redman, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Megan Hull",
                            "role": "CONTACT",
                            "phone": "734-232-2561",
                            "email": "meghull@med.umich.edu"
                        },
                        {
                            "name": "Francis Worden, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Supraja Chalasani",
                            "role": "CONTACT",
                            "phone": "313-576-9732",
                            "email": "chalasas@karmanos.org"
                        },
                        {
                            "name": "Ammar Sukari, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Washington University",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Samuel Williams",
                            "role": "CONTACT",
                            "phone": "314-747-2626",
                            "email": "wsamuel@wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins, MD",
                            "role": "CONTACT",
                            "phone": "314.747.2626",
                            "email": "dadkins@wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "START- San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Gomez",
                            "role": "CONTACT",
                            "phone": "210-593-5994",
                            "email": "elizabeth.gomez@startsa.com"
                        },
                        {
                            "name": "Amita Patnaik, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "START Mountain",
                    "status": "RECRUITING",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marianne Herden",
                            "role": "CONTACT",
                            "phone": "801-907-4753",
                            "email": "marianne.herndon@startthecure.com"
                        },
                        {
                            "name": "Justin Call, MD",
                            "role": "CONTACT",
                            "phone": "801-907-4753",
                            "email": "justin.call@startthecure.com"
                        },
                        {
                            "name": "Justin Call, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                },
                {
                    "facility": "University of Washington/Fred Hutchinson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ariana Dumenigo Jimenez",
                            "role": "CONTACT",
                            "phone": "206-606-7445",
                            "email": "adumenigoj@fredhutch.org"
                        },
                        {
                            "name": "Christina Rodriguez, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}